03/22/2006
Federal Register Final rule: FDA is issuing an order prohibiting the extralabel use of anti-influenza adamantane and neuraminidase...03/17/2006
Federal Register Notice: FDA is publishing a list of premarket approval applications that have been approved and informing the pub...03/17/2006
Federal Register Notice: FDA is canceling the meeting of the Manufacturing Subcommittee of the Advisory Committee for Pharmaceutic...03/15/2006
Federal Register Notice: FDA is making available a guidance for industry entitled Nonclinical Safety Evaluation of Drug or Biologi...03/15/2006
Federal Register Notice: FDA has determined the regulatory review period for Genzyme Corp.’s Ovidrel is 1,787 days for extending a...03/15/2006
Federal Register Notice: FDA has determined the regulatory review period for AstraZeneca’s cholesterol-lowering drug Crestor (rosu...03/15/2006
Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Relpax (eletriptan hydrobromide) is 2,829 da...03/15/2006
Federal Register Notice: FDA has determined the regulatory review period for Elan Pharmaceuticals’ Prialt (ziconotide) is 3,801 da...